ARCHIMED

• ARCHIMED to Acquire Esperion Therapeutics in Up to $1.1B Deal

  May 1, 2026

  Buyer

  ARCHIMED

  Target

  Esperion Therapeutics

  Industry

  Healthcare Services

  Location

  Michigan, United States

  Type

  Buyout

  ARCHIMED, via a fund-managed affiliate, signed a definitive agreement to acquire Esperion Therapeutics for $3.16 per share in cash, valuing the transaction at up to approximately $1.1 billion including commercial milestone payments. Esperion shareholders will also receive a contingent value right (CVR) for up to $100 million in additional milestones tied to future U.S. net sales of bempedoic acid- and bumetanide-containing products.

• ARCHIMED Diagnostics (with La Caisse) Acquires Stago

  April 29, 2026

  Buyer

  ARCHIMED Diagnostics, La Caisse, ARCHIMED (MED Platform II fund)

  Target

  Stago

  Seller

  Viret family

  Industry

  Healthcare Services

  Location

  France

  Type

  Buyout

  ARCHIMED Diagnostics, alongside global investment group La Caisse (minority investor), has purchased Stago, a global leader in blood coagulation (hemostasis) analysis. The investment is held through ARCHIMED’s MED Platform II fund, with Stago’s leadership taking a minority stake as part of the deal.

• Rhône Acquires Invacare Europe and Direct Healthcare Group to Create DHCare

  January 30, 2026

  Buyer

  Rhône, ARCHIMED

  Target

  Invacare Holdings S.ar.l. (Invacare Europe & APAC), Direct Healthcare Group (DHG)

  Industry

  Medical Devices

  Location

  United Kingdom

  Type

  Buyout

  Rhône has completed acquisitions of Invacare Holdings S.ar.l. (Invacare Europe & APAC) and Direct Healthcare Group (DHG) through vehicles held by its Fund VI and combined the businesses to form DHCare, a London‑headquartered medical device platform. The transaction closed January 30, 2026; ARCHIMED will retain a minority stake in the newly formed company, which expands the combined product portfolio across mobility, seating, pressure‑care, patient handling and rental/services.

• ARCHIMED Diagnostics Acquires 60% Stake in ARK Diagnostics

  October 28, 2025

  Buyer

  ARCHIMED Diagnostics (ARCHIMED MED Platform II)

  Target

  ARK Diagnostics

  Seller

  Soulbrain Holdings

  Industry

  Medical Devices

  Location

  California, United States

  Type

  Buyout

  ARCHIMED Diagnostics (ARCHIMED’s diagnostics team) has acquired a 60% stake in Fremont-based ARK Diagnostics from Soulbrain Holdings in a transaction valuing ARK at $428 million. Soulbrain retains and reinvests in a 40% stake and the deal includes a joint-venture agreement to accelerate ARK’s product development and global expansion.

• ARCHIMED to Take ZimVie Private in $730 Million Deal

  October 20, 2025

  Buyer

  ARCHIMED (affiliate of ARCHIMED, via MED Platform II fund)

  Target

  ZimVie

  Industry

  Medical Devices

  Location

  Florida, United States

  Type

  Buyout

  ARCHIMED, via an affiliate and its MED Platform II fund, has agreed to acquire NASDAQ-listed ZimVie in a take-private transaction valued at approximately $730 million. ZimVie shareholders will receive $19.00 in cash per share, with the deal expected to close by the end of 2025 subject to customary approvals.

• ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics

  September 25, 2025

  Buyer

  ARCHIMED

  Target

  ExcellGene SA, Magellan Biologics & Consulting Lda

  Seller

  Founders Florian and Maria Wurm and other family shareholders

  Industry

  Biotechnology

  Location

  Valais, Switzerland

  Type

  Buyout

  ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.

• ARCHIMED Acquires Groupe Laboratoire Rivadis

  September 8, 2025

  Buyer

  ARCHIMED

  Target

  Groupe Laboratoire Rivadis

  Seller

  Christian Lainé (majority shareholder)

  Industry

  Consumer Products

  Location

  Nouvelle-Aquitaine, France

  Type

  Buyout

  ARCHIMED, a healthcare-focused private equity firm, has acquired Groupe Laboratoire Rivadis, a French developer and manufacturer of dermo-cosmetics and hygiene products (brands include Rivadouce, Milton and Auriège). The seller, majority shareholder Christian Lainé, is reinvesting a meaningful portion of proceeds; ARCHIMED plans to support Rivadis' growth and strengthen its position in the consumer health / dermo-cosmetics market.

• ARCHIMED Acquires Majority Stake in Arkstone Medical Solutions

  August 6, 2025

  Buyer

  ARCHIMED

  Target

  Arkstone Medical Solutions

  Industry

  Healthcare Services

  Location

  North Carolina, United States

  Type

  Buyout

  ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Arkstone Medical Solutions, a provider of AI/ML-driven clinical decision support and antimicrobial stewardship tools. The investment will support Arkstone's product development, global expansion and R&D to accelerate adoption of its OneChoice Report in laboratories and healthcare providers worldwide.

• ARCHIMED Acquires BioVendor Group

  March 11, 2025

  Buyer

  ARCHIMED

  Target

  BioVendor Group

  Industry

  Medical Devices

  Location

  Czech Republic

  Type

  Buyout

  ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

• Cube Biotech Acquires IBA Lifesciences GmbH

  January 13, 2025

  Buyer

  Cube Biotech GmbH, ARCHIMED

  Target

  IBA Lifesciences GmbH

  Industry

  Biotechnology

  Location

  Germany

  Type

  Addon

  Cube Biotech, a portfolio company of ARCHIMED, has acquired IBA Lifesciences GmbH, a German life‑science tools company known for its Strep‑Tag affinity technology. The deal expands Cube's protein purification product portfolio and strengthens its position in affinity‑tag purification technologies to better serve academic and industry researchers worldwide.

• ARCHIMED Acquires SeqCenter, Next-Generation Sequencing Provider

  November 8, 2024

  Buyer

  ARCHIMED

  Target

  SeqCenter

  Industry

  Biotechnology

  Location

  Pennsylvania, United States

  Type

  Buyout

  Global healthcare private equity firm ARCHIMED has acquired SeqCenter, a Pittsburgh, Pennsylvania-based provider of next-generation DNA and RNA sequencing, through its MED Rise fund. ARCHIMED will leverage its MedValue playbook to accelerate SeqCenter's internationalization in Europe and Asia and support further development of advanced sequencing technologies; SeqCenter's founder rolled over a significant portion of his proceeds into the business.

• ARCHIMED Acquires FIM Medical

  October 15, 2024

  Buyer

  ARCHIMED

  Target

  FIM Medical

  Industry

  Medical Devices

  Location

  Auvergne-Rhône-Alpes, France

  Type

  Buyout

  ARCHIMED, a healthcare-focused private equity firm, has acquired FIM Medical, a Lyon-based leader in occupational health medical devices specializing in vision testers, audiometers and spirometers. The acquisition, executed by ARCHIMED's MED Rise fund, positions the firm to strengthen its neuro & sensory and occupational health capabilities and support FIM Medical's international expansion.

Related Acquisition Pages